Find Clinical Trials

May 10, 2023 in Cancer Control / CCDR

S2010

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer…
Read More
April 18, 2023 in Cancer Control / CCDR

CC010

A Phase III Trial of the Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer
Read More
December 19, 2022 in Cancer Control / CCDR

A212102

A212102 Blinded Reference Set For Multicancer Early Detection Blood Tests
Read More
November 30, 2022 in Cancer Control / CCDR

S2108CD

A CLUSTER RANDOMIZED TRIAL COMPARING AN EDUCATIONALLY ENHANCED GENOMIC TUMOR BOARD (EGTB) INTERVENTION TO USUAL PRACTICE TO INCREASE EVIDENCE-BASED GENOME-INFORMED THERAPY
Read More
November 22, 2022 in Cancer Control / CCDR

U21038

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
Read More
September 14, 2022 in Cancer Control / CCDR

A231602CD

Improving surgical care and outcomes in Older cancer Patients Through Implementation of an efficient pre-Surgical toolkit (OPTI-Surg)
Read More
August 10, 2022 in Cancer Control / CCDR

A222004

A222004: A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia (NCT04939090)
Read More
July 11, 2022 in Cancer Control / CCDR

WF1805CD

WF1805CD: Implementation and Effectiveness Trial of HN-STAR
Read More
July 11, 2022 in Cancer Control / CCDR

WF1801

Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Read More
July 11, 2022 in Cancer Control / CCDR

U19185

U19185: Multicenter Randomized Controlled Trial comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
Read More
July 11, 2022 in Cancer Control / CCDR

U18007

U18007: Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue
Read More
July 11, 2022 in Cancer Control / CCDR

U16070

Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
Read More
July 11, 2022 in Cancer Control / CCDR

S1912CD

S1912CD: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
Read More
July 11, 2022 in Cancer Control / CCDR

S1600

S1600: A Randomized Phase III Double Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
Read More
July 11, 2022 in Cancer Control / CCDR

S1501

Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
Read More
July 1, 2022 in Cancer Control / CCDR

S0820

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrance of High Risk Adenomas and Secondary Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III-Preventing…
Read More
July 1, 2022 in Cancer Control / CCDR

NHLBI-MDS

The National Myelodysplastic Syndromes Natural History Study
Read More
June 30, 2022 in Cancer Control / CCDR

EAQ202

EAQ202: Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Read More
June 30, 2022 in Cancer Control / CCDR

EA1151

Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer (TMIST)
Read More
June 30, 2022 in Cancer Control / CCDR

CC008

CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (NCT # 04251052)
Read More
June 30, 2022 in Cancer Control / CCDR

CC005/FORTE

CC005, FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)
Read More
June 30, 2022 in Cancer Control / CCDR

A222001

A222001: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy (NCT04600336)
Read More
June 30, 2022 in Cancer Control / CCDR

A221805

A221805: Duloxetine To Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Bind, Placebo-Controlled Phase II To Phase III Study (NCT # 04137107)
Read More
June 30, 2022 in Cancer Control / CCDR

A211901

A211901: Reaching Rural Cancer Survivors Who Smoke using Text-Based Cessation Interventions (NCT# 05008848)
Read More
June 30, 2022 in Cancer Control / CCDR

A191901

A191901: Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions (NCT # 04379570)
Read More